Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of Friday, August 7, 2026.
Forward PE Ratio (N/A) = Close Price ($7.09) / Consensus Forward EPS ($-0.87)
FORWARD PE RATIO
N/A
Teladoc Health, Inc.
Market Cap
$1.29B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Teladoc Health, Inc. (TDOC) | $1.29B | N/A |
| NRC Health (NRC)vs › | $453.77M | 22.13 |
| Shoulder Innovations, Inc. (SI)vs › | $408.96M | N/A |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $2.44B | 9.28 |
| 23andMe Holding Co. (ME)vs › | $15.31M | N/A |
| TransMedics Group, Inc. (TMDX)vs › | $2.79B | 43.85 |
| Hims & Hers Health, Inc. (HIMS)vs › | $6.93B | N/A |
| Oscar Health, Inc. (OSCR)vs › | $7.11B | 24.04 |
| Tempus AI, Inc. (TEM)vs › | $8.83B | N/A |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $9.34B | 37.87 |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus next-FY EPS
At today's $7.09 close, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.87 | $-1.01 – $-0.76 | 10 | n/m |
| 2027-12-31 | $-0.62 | $-0.98 – $-0.40 | 10 | n/m |
| 2028-12-31 | $-0.50 | $-1.04 – $0.28 | 9 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
